Alison Bauerlein Sells 1,200 Shares of Inogen, Inc. (NASDAQ:INGN) Stock


Share on StockTwits

Inogen, Inc. (NASDAQ:INGN) CFO Alison Bauerlein sold 1,200 shares of Inogen stock in a transaction that occurred on Tuesday, April 13th. The stock was sold at an average price of $60.00, for a total value of $72,000.00. Following the transaction, the chief financial officer now owns 4,524 shares of the company’s stock, valued at $271,440. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Alison Bauerlein also recently made the following trade(s):

  • On Monday, March 15th, Alison Bauerlein sold 18,098 shares of Inogen stock. The stock was sold at an average price of $52.23, for a total value of $945,258.54.
  • On Tuesday, February 16th, Alison Bauerlein sold 18,098 shares of Inogen stock. The stock was sold at an average price of $53.88, for a total value of $975,120.24.
  • On Tuesday, January 26th, Alison Bauerlein sold 8,973 shares of Inogen stock. The shares were sold at an average price of $50.04, for a total value of $449,008.92.
  • On Friday, January 15th, Alison Bauerlein sold 18,098 shares of Inogen stock. The shares were sold at an average price of $44.34, for a total value of $802,465.32.

Shares of NASDAQ INGN opened at $65.73 on Friday. The stock has a market capitalization of $1.47 billion, a PE ratio of -730.25 and a beta of 1.05. The business has a fifty day moving average price of $51.58 and a two-hundred day moving average price of $42.93. Inogen, Inc. has a fifty-two week low of $26.57 and a fifty-two week high of $66.07.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Wednesday, February 24th. The medical technology company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. Inogen had a positive return on equity of 0.21% and a negative net margin of 0.66%. The company had revenue of $73.98 million during the quarter, compared to analysts’ expectations of $69.19 million. As a group, equities research analysts expect that Inogen, Inc. will post -0.31 earnings per share for the current fiscal year.

Several research firms recently issued reports on INGN. Zacks Investment Research upgraded Inogen from a “sell” rating to a “hold” rating and set a $59.00 price target for the company in a research note on Monday, February 15th. SVB Leerink boosted their price target on Inogen from $47.00 to $54.00 and gave the company a “market perform” rating in a research note on Wednesday, March 3rd. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $62.00.

Several institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its holdings in shares of Inogen by 105.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 780 shares of the medical technology company’s stock worth $35,000 after buying an additional 400 shares in the last quarter. Exchange Traded Concepts LLC grew its position in Inogen by 4.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 9,926 shares of the medical technology company’s stock worth $443,000 after acquiring an additional 450 shares during the last quarter. Inspire Advisors LLC bought a new stake in Inogen during the 4th quarter worth $28,000. Charles Schwab Investment Management Inc. grew its position in Inogen by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 121,708 shares of the medical technology company’s stock worth $5,438,000 after acquiring an additional 693 shares during the last quarter. Finally, Royce & Associates LP grew its position in Inogen by 7.7% during the 4th quarter. Royce & Associates LP now owns 9,932 shares of the medical technology company’s stock worth $444,000 after acquiring an additional 712 shares during the last quarter. 95.07% of the stock is owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: ESG Score

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.